(Albany, US) DelveInsight has launched a new report on “Hepatic Encephalopathy – Market Insights, Epidemiology, and Market Forecast-2030″
DelveInsight’s “Hepatic Encephalopathy – Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the Hepatic Encephalopathy, historical and forecasted epidemiology as well as the Hepatic Encephalopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the report:
Request for free sample report: https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market
Scope of the Report
Hepatic Encephalopathy (HE), sometimes referred to as portosystemic encephalopathy or PSE, is a condition that causes temporary worsening of brain function in people with advanced liver disease. It occurs in individuals with liver disease when toxins that are normally cleared in the liver accumulate in the blood eventually traveling to and damaging the brain. The condition can decrease mental function and cause stupor and even coma.
HE is clinically classified into three major categories, according to the underlying hepatic condition:
– Type A: Encephalopathy from acute liver failure
– Type B: Encephalopathy caused by portosystemic shunting, without intrinsic liver disease
– Type C: Encephalopathy of cirrhosis associated with portosystemic shunting
A number of scales have been designed for the diagnosis of HE, among which West-Haven Criteria is most commonly used:
Grade 0: Minimal HE, Grade 1: Mild HE [Covert HE stages], Grade 2: Moderate HE, Grade 3: Severe HE, Grade 5: Coma [Overt HE stages]
Drugs covered
The key players in Hepatic Encephalopathy market are:
Reasons to buy
Table of contents:
1. Key Insights
2. Executive Summary of Hepatic Encephalopathy
3. Competitive Intelligence Analysis for Hepatic Encephalopathy
4. Hepatic Encephalopathy: Market Overview at a Glance
4.1. Hepatic Encephalopathy Total Market Share (%) Distribution in 2017
4.2. Hepatic Encephalopathy Total Market Share (%) Distribution in 2030
5. Hepatic Encephalopathy: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Hepatic Encephalopathy Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Hepatic Encephalopathy Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Hepatic Encephalopathy Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Hepatic Encephalopathy Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Hepatic Encephalopathy Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Hepatic Encephalopathy Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Hepatic Encephalopathy Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Hepatic Encephalopathy Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Hepatic Encephalopathy Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Hepatic Encephalopathy Treatment and Management
8.2. Hepatic Encephalopathy Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Hepatic Encephalopathy Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
13. Hepatic Encephalopathy: Seven Major Market Analysis
13.1. Key Findings
13.2. Hepatic Encephalopathy Market Size in 7MM
13.3. Hepatic Encephalopathy Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Hepatic Encephalopathy Total Market Size in the United States
15.1.2. Hepatic Encephalopathy Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Hepatic Encephalopathy Total Market Size in Germany
15.3.2. Hepatic Encephalopathy Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Hepatic Encephalopathy Total Market Size in France
15.4.2. Hepatic Encephalopathy Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Hepatic Encephalopathy Total Market Size in Italy
15.5.2. Hepatic Encephalopathy Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Hepatic Encephalopathy Total Market Size in Spain
15.6.2. Hepatic Encephalopathy Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Hepatic Encephalopathy Total Market Size in the United Kingdom
15.7.2. Hepatic Encephalopathy Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Hepatic Encephalopathy Total Market Size in Japan
15.8.3. Hepatic Encephalopathy Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Hepatic Encephalopathy
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/hepatic-encephalopathy-market